Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307180 | 0.83 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1SMN1; SMN2PPARGRAB9A | |
| SCHEMBL6315157 | 0.77 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1PPARGDHFRADORA2A | |
| SCHEMBL6309423 | 0.74 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1DHFRADORA2AADORA1 | |
| SCHEMBL3635237 | 0.73 | TSHR (0.54) | SMN1; SMN2SIGMAR1TSHR | |
| SCHEMBL26317585 | 0.73 | NPC1 (0.56) | SMN1; SMN2RAB9AADORA2A | |
| SCHEMBL21530452 | 0.72 | ALDH1A1 (0.48) | SMN1; SMN2RAB9AADORA2A | |
| SCHEMBL3160936 | 0.71 | MAOB (0.52) | RAB9AADORA2AADORA1SIGMAR1TSHR | |
| SCHEMBL6315317 | 0.70 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1SMN1; SMN2RAB9AADORA2A | |
| SCHEMBL6315250 | 0.69 | NPC1 (0.71) | HSP90AA1HSP90AB1SMN1; SMN2RAB9A | |
| SCHEMBL31612527 | 0.66 | CYP2C19 (0.55) | SMN1; SMN2SIGMAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919339-B2 | ABCA-1 elevating compounds | CV THEAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1341773-A2 | SUBSTITUTED 1,3,5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020128266-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002046172-A2 | SUBSTITUTED 1, 3, 5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128266-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | HSP90AA1 1676/4885HSP90AB1 1191/4885SMN1; SMN2 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.